Difference between revisions of "Estrogen receptor"

From Cysteinome
Jump to: navigation, search
(Created page with "{| align="left" | __TOC__ |} {{#invoke:InfoboxforTarget|run|VDR, NR1I1|[https://www.uniprot.org/uniprot/P11473 P11473]|Homo sapiens|Cys417, Cys530|[http://pfam.xfam.org/fa...")
 
(Reference)
Line 70: Line 70:
 
[[Category:Pathways in cancer|Pathways in cancer]]
 
[[Category:Pathways in cancer|Pathways in cancer]]
 
[[Category:Proteoglycans in cancer|Proteoglycans in cancer]]
 
[[Category:Proteoglycans in cancer|Proteoglycans in cancer]]
[[Category:PBreast cancer|Breast cancer]]
+
[[Category:Breast cancer|Breast cancer]]

Revision as of 20:58, 19 August 2019

Basic Information
Short Name VDR, NR1I1
UNP ID P11473
Organism Homo sapiens
Cys Site Cys417, Cys530
Family/Domain Ligand-binding domain of nuclear hormone receptor,
Nuclear hormone receptor family,
NR3 subfamily
Known Ligand Ligand list
Function Type Transcription Related, Metabolic enzyme

Summary

Protein Function

Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. (From Uniprot)

Cys Function & Property

Cys288 is very close to the active site of VDR in space.

  • Hydrophobic property:
575-hydro.png
  • SASA:
Cys417: 55.382 A^2
Cys530: 73.207 A^2


Protein Sequence

MTMTLHTKAS GMALLHQIQG NELEPLNRPQ LKIPLERPLG EVYLDSSKPA
VYNYPEGAAY EFNAAAAANA QVYGQTGLPY GPGSEAAAFG SNGLGGFPPL
NSVSPSPLML LHPPPQLSPF LQPHGQQVPY YLENEPSGYT VREAGPPAFY
RPNSDNRRQG GRERLASTND KGSMAMESAK ETRYCAVCND YASGYHYGVW
SCEGCKAFFK RSIQGHNDYM CPATNQCTID KNRRKSCQAC RLRKCYEVGM
MKGGIRKDRR GGRMLKHKRQ RDDGEGRGEV GSAGDMRAAN LWPSPLMIKR
SKKNSLALSL TADQMVSALL DAEPPILYSE YDPTRPFSEA SMMGLLTNLA
DRELVHMINW AKRVPGFVDL TLHDQVHLLE CAWLEILMIG LVWRSMEHPG
KLLFAPNLLL DRNQGKCVEG MVEIFDMLLA TSSRFRMMNL QGEEFVCLKS
IILLNSGVYT FLSSTLKSLE EKDHIHRVLD KITDTLIHLM AKAGLTLQQQ
HQRLAQLLLI LSHIRHMSNK GMEHLYSMKC KNVVPLYDLL LEMLDAHRLH
APTSRGGASV EETDQSHLAT AGSTSSHSLQ KYYITGEAEG FPATV

Structural Information

  • Known structure with covalent ligand:
Unknown
  • Protein structure:
575.png

Related Pathway

Experimental Evidence

Cys-directed Mutation

Reference

  1. Aliau S, El Garrouj D, Yasri A, et al. 17α-(Haloacetamidoalkyl) estradiols alkylate the human estrogen receptor at cysteine residues 417 and 530[J]. Biochemistry, 1997, 36(19): 5861-5867. 9153427